Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 16;2(1):vdaa088. doi: 10.1093/noajnl/vdaa088

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 1. — Phylogenies of IDH-mutant astrocytoma and oligodendroglioma PDCs, scPDCs, and PDX integrated with spatiotemporal tumor tissue samples. (A, upper panel): The clinical timeline of astrocytoma Patient 137, drawn to scale. Vertical lines indicate surgical resection; stars represent radiographic progression; filled rectangles indicate treatment period and fill color indicates treatment type (see key at bottom). Months between surgical resections are provided below the timeline. The tumor classification is listed above each surgical time point, and surgeries from which samples were sequenced are designated with an SF number. Lower panel: A tumor phylogeny was constructed from single-nucleotide somatic mutations. Line length is proportional to the number of mutations. Lowest panel: A zoomed-in view of the shaded portion of the tree showing the relationship between samples of the non-HM first tumor recurrence (SF10071) and the HM samples of the second recurrence (SF10602). (B, upper panel): The clinical timeline of oligodendroglioma Patient 278. Lower panel: A tumor phylogeny of tumor tissue and PDCs of Patient 278. FBS, cells cultured in media containing fetal bovine serum; GNS, cells cultured in glioma neural stem cell media; PDCs, patient-derived cells; scPDCs, single-cell-derived patient-derived cells; PDC-LUC, luciferase-modified PDC; T1, T2, T3, spatially distinct pieces of tumor tissue; PDX, patient-derived intracranial xenograft; PDX-PDC, PDC derived from PDX; A, astrocytoma; O, oligodendroglioma; TMZ, temozolomide; XRT, radiation therapy; CCNU, lomustine; P#, passage number.